GlassScriptPhysician profile
Juli Kang
NPI 1174398689
$759.68
in general payments reported to CMS, 2019-2025
13 companies · $315 in 2025
The $315 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $16.67 · 2024: $428 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $759.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $300.40 | 2024-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $150.60 | 2024 | Farxiga |
| Novo Nordisk INC | $51.13 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Ibsa Pharma INC. | $48.52 | 2024-2025 | Tirosint, Licart, Flector |
| Lilly USA, LLC | $39.04 | 2024-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $37.60 | 2024-2025 | Rexulti |
| Aimmune Therapeutics, INC. | $32.24 | 2024-2025 | Zenpep |
| Ani Pharmaceuticals, INC. | $20.91 | 2025 | Purified Cortrophin Gel |
| Scilex Pharmaceuticals INC. | $17.56 | 2024 | |
| Azurity Pharmaceuticals, INC. | $16.84 | 2024 | Edarbi |
| Averitas Pharma INC. | $15.79 | 2025 | Qutenza |
| Abbvie INC. | $15.25 | 2024 | |
| Vivus LLC | $13.80 | 2024 | Pancreaze |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juli Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.